Related Experiment Video

Updated: Aug 18, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

[Aromatase inhibitors--new horizons in breast cancer endocrine therapy]

Hiba Basić-Cabaravdić1

  • 1Institut za onkologiju, Klinicki centar Univerziteta u Sarajevu, Bosna i Hercegovina.

Medicinski Arhiv
|April 13, 2005
PubMed

Insights

Hormonal therapies like tamoxifen and aromatase inhibitors have significantly reduced breast cancer mortality. While aromatase inhibitors show promise in early-stage treatment, tamoxifen remains the standard for endocrine-dependent breast cancer.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Context:

  • Estrogen (ER) and progesterone (PgR) receptors are present in a significant percentage of breast cancers, rendering them hormone-dependent.
  • Hormonal therapies have drastically decreased mortality rates for hormone-responsive breast cancer.
  • Tamoxifen, an ER blocker, has been a cornerstone in treatment, alongside newer aromatase inhibitors (AIs).

Purpose:

  • To review the role of hormonal therapies in treating hormone-dependent breast cancer.
  • To compare the efficacy and side effects of tamoxifen and third-generation nonsteroidal aromatase inhibitors.
  • To discuss the current investigations into AI use in early breast cancer adjuvant therapy.

Summary:

  • Hormone-dependent breast cancers are treated with drugs targeting estrogen receptors or synthesis.
  • Third-generation aromatase inhibitors are effective in advanced breast cancer for postmenopausal women, showing advantages over tamoxifen.
  • Research is ongoing to evaluate aromatase inhibitors for early breast cancer adjuvant therapy and their associated side effects.

Impact:

  • Hormonal therapies have significantly improved survival rates for patients with hormone-dependent breast cancer.
  • The development of aromatase inhibitors offers new treatment options, particularly for postmenopausal women.
  • Ongoing research aims to optimize adjuvant endocrine therapy for early breast cancer, balancing efficacy and patient safety.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...